5th generation glp 1 What is the pipeline for future medications for obesity? GLP-1 Medications for Weight Loss:

BioMed Research International, 2015 Pickart L

Important Rule Wegovy and Zepbound are not covered by Medicare for obesity

Summary of Nutrient Risk Patterns Across nutrients reviewed: No strong evidence of universal deficiency Risk is intake-driven rather than absorption-driven Rapid weight loss increases vulnerability Pre-existing marginal status matters Long-term micronutrient data remain limited The next section will examine the clinical evidence base in greater detail, including trial data, observational findings and limitations

Onset Timing: They can develop gradually and persist for several hours or even days

Its much higher than the daily need of 2.4 mcg for adults

10.1038/sj.bjp.0704602 14 DeaconC